Metabolic syndrome as a peculiar target for management of prostate cancer patients.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Clinical Genitourinary Cancer

• Publication date

  2013-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.clgc.2013.04.009PMID 23701880
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Metabolic complications of androgen deprivation therapy for prostate cancer.

  2013cited by this paper
• The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy.

  2013cited by this paper
• Insulin-like growth factor pathway: a link between androgen deprivation therapy (ADT), insulin resistance, and disease progression in patients with prostate cancer?

  2013cited by this paper
• Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis.

  2012cited by this paper
• A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy

  2012cited by this paper
• Cancer statistics, 2012

  2012cited by this paper
• Molecular imaging of prostate cancer: PET radiotracers.

  2012cited by this paper
• Combination of Rad001 (Everolimus) and Propachlor Synergistically Induces Apoptosis through Enhanced Autophagy in Prostate Cancer Cells

  2012cited by this paper
• Targeting the skeletal muscle-metabolism axis in prostate-cancer therapy.

  2012cited by this paper
• Statin Use and Risk of Prostate Cancer: A Meta-Analysis of Observational Studies

  2012cited by this paper
• The Interactions between Insulin and Androgens in Progression to Castrate-Resistant Prostate Cancer

  2012cited by this paper
• The influence of antidiabetic medications on the development and progression of prostate cancer.

  2012cited by this paper
• Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway.

  2012cited by this paper
• Presence of the metabolic syndrome is associated with shorter time to castration-resistant prostate cancer.

  2011cited by this paper
• The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis

  2011cited by this paper
• The effects of metabolic conditions on prostate cancer incidence over 15 years of follow‐up: results from the Olmsted County Study

  2011cited by this paper
• Metabolic alterations and targeted therapies in prostate cancer

  2011cited by this paper
• Understanding the benefit of metformin use in cancer treatment

  2011cited by this paper
• CaM kinase kinase beta-mediated activation of the growth regulatory kinase AMPK is required for androgen-dependent migration of prostate cancer cells.

  2011cited by this paper
• Does physical activity reduce the risk of prostate cancer? A systematic review and meta-analysis.

  2011cited by this paper
• Body Mass Index, Prostate Cancer–Specific Mortality, and Biochemical Recurrence: a Systematic Review and Meta-analysis

  2011cited by this paper
• The Link between the Metabolic Syndrome and Cancer

  2011cited by this paper
• Impact of comorbidity on survival among men with localized prostate cancer.

  2011cited by this paper
• Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1.

  2011cited by this paper
• Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials.

  2011cited by this paper
• Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer.

  2011cited by this paper
• Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients.

  2011cited by this paper
• Metformin in prostate cancer: two for the price of one.

  2011cited by this paper
• AMPK exerts dual regulatory effects on the PI3K pathway

  2010cited by this paper
• The PI3K pathway as drug target in human cancer.

  2010cited by this paper
• Care of the cancer survivor: metabolic syndrome after hormone-modifying therapy.

  2010cited by this paper
• Integrative genomic profiling of human prostate cancer.

  2010cited by this paper
• The impact of an aromatase inhibitor on body composition and gonadal hormone levels in women with breast cancer

  2010cited by this paper
• Prostate cancer and PSA among statin users in the Finnish prostate cancer screening trial

  2010cited by this paper
• Metformin Associated With Lower Cancer Mortality in Type 2 Diabetes: ZODIAC-16

  2010cited by this paper
• A 25-year prospective study of plasma adiponectin and leptin concentrations and prostate cancer risk and survival.

  2010cited by this paper
• PI3K-AKT-mTOR Pathway is Dominant over Androgen Receptor Signaling in Prostate Cancer Cells

  2010cited by this paper
• Metabolic sequelae associated with androgen deprivation therapy for prostate cancer

  2010cited by this paper
• Association of diabetes with prostate cancer risk in the multiethnic cohort.

  2009cited by this paper
• Metformin Associated With Lower Cancer Mortality in Type 2 Diabetes

  2009cited by this paper
• Metformin use and prostate cancer in Caucasian men: results from a population-based case–control study

  2009cited by this paper
• Metabolic complications of androgen deprivation therapy for prostate cancer.

  2009cited by this paper
• Racial differences in risk of prostate cancer associated with metabolic syndrome.

  2009cited by this paper
• Effects of hormonal treatment on lipids in patients with cancer.

  2009cited by this paper
• Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway.

  2009cited by this paper
• Metabolic Changes During Gonadotropin-releasing Hormone Agonist Therapy For Prostate Cancer: Differences From the Classic Metabolic Syndrome

  2009cited by this paper
• Dietary intervention strategies to modulate prostate cancer risk and prognosis

  2009cited by this paper
• Review of major adverse effects of androgen‐deprivation therapy in men with prostate cancer

  2009cited by this paper
• Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction.

  2009cited by this paper
• Metabolic changes during gonadotropin‐releasing hormone agonist therapy for prostate cancer

  2008cited by this paper
• Obesity and positive surgical margins by anatomic location after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital database

  2008cited by this paper
• The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level

  2008cited by this paper
• Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.

  2008cited by this paper
• Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features.

  2008cited by this paper
• A pilot dose‐escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer

  2008cited by this paper
• Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis.

  2008cited by this paper
• Diabetes mellitus and prostate cancer risk

  2008cited by this paper
• Insulin and insulin-like growth factor signalling in neoplasia

  2008cited by this paper
• Inflammation in prostate carcinogenesis

  2007cited by this paper
• Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial.

  2007cited by this paper
• The Prostate 68 : 11 ^ 19 ( 2008 ) Carbohydrate Restriction , ProstateCancerGrowth , andthe Insulin-LikeGrowth FactorAxis

  2007cited by this paper
• Inverse correlation between body mass index and clinical outcomes in men with advanced castration–recurrent prostate cancer

  2007cited by this paper
• Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle‐aged men

  2007cited by this paper
• Obesity and prostate cancer: epidemiology and clinical implications.

  2007cited by this paper
• History of diabetes mellitus and subsequent prostate cancer risk in the NIH-AARP Diet and Health Study

  2007cited by this paper
• Metabolic syndrome predicts prostate cancer in a cohort of middle-aged Norwegian men followed for 27 years.

  2006cited by this paper
• Obesity, Diabetes, and Risk of Prostate Cancer: Results from the Prostate Cancer Prevention Trial

  2006cited by this paper
• Increased Cancer-Related Mortality for Patients With Type 2 Diabetes Who Use Sulfonylureas or Insulin

  2006cited by this paper
• Self-reported history of hypercholesterolaemia and gallstones and the risk of prostate cancer.

  2006cited by this paper
• Insulin-Like Growth Factor (IGF) family and prostate cancer.

  2006cited by this paper
• Metabolic syndrome.

  2006cited by this paper
• Insulin sensitivity during combined androgen blockade for prostate cancer.

  2006cited by this paper
• Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy.

  2006cited by this paper
• A Meta-analysis of Diabetes Mellitus and the Risk of Prostate Cancer

  2006cited by this paper
• The metabolic syndrome is associated with reduced risk of prostate cancer.

  2006cited by this paper
• Hyperinsulinaemia: a prospective risk factor for lethal clinical prostate cancer.

  2005cited by this paper
• Metformin and reduced risk of cancer in diabetic patients

  2005cited by this paper
• Impact of obesity on prostate cancer recurrence after radical prostatectomy: data from CaPSURE.

  2005cited by this paper
• Diabetes and risk of prostate cancer in a prospective cohort of US men.

  2005cited by this paper
• The Effect of Metformin and Intensive Lifestyle Intervention on the Metabolic Syndrome: The Diabetes Prevention Program Randomized Trial

  2005cited by this paper
• Obesity and Prostate Cancer: A Growing Problem

  2005cited by this paper
• Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate‐specific antigen level after radical prostatectomy and/or radiation therapy

  2004cited by this paper
• Metabolic syndrome and the risk of prostate cancer in Finnish men: a population-based study.

  2004cited by this paper
• Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy.

  2004cited by this paper
• Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition

  2004cited by this paper
• High levels of circulating insulin-like growth factor-I increase prostate cancer risk: a prospective study in a population-based nonscreened cohort.

  2004cited by this paper
• Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition

  2004cited by this paper
• Testosterone is a potent inhibitor of L-type Ca(2+) channels.

  2004cited by this paper
• Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men.

  2004cited by this paper
• Clinical, haemodynamic, anthropometric, metabolic and insulin profile of men with high‐stage and high‐grade clinical prostate cancer

  2004cited by this paper
• The mechanisms of androgen effects on body composition: mesenchymal pluripotent cell as the target of androgen action.

  2003cited by this paper
• Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia.

  2003cited by this paper
• The insulin-like growth factor system and cancer.

  2003cited by this paper
• The metabolic syndrome.

  2003cited by this paper
• Changes in body composition during androgen deprivation therapy for prostate cancer.

  2002cited by this paper
• Increased serum insulin associated with increased risk of prostate cancer recurrence

  2002cited by this paper
• The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer.

  2001cited by this paper
• Relationships between tamoxifen use, liver fat and body fat distribution in women with breast cancer

  2001cited by this paper
• Hypertension, heart rate, use of antihypertensives, and incident prostate cancer.

  2001cited by this paper
• Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study.

  1998cited by this paper

• Metabolic crosstalk in the metastatic prostate cancer-bone microenvironment: mechanism, detection and therapeutic strategies.

  2026cites this paper
• Sex difference in human diseases: mechanistic insights and clinical implications

  2024cites this paper
• The gerontological saga of antidiabetic biguanides: from ignorance to prudence via high hopes

  2024cites this paper
• Role of Metabolism and Metabolic Pathways in Prostate Cancer

  2023cites this paper
• The Effect of Metformin on Male Reproductive Function and Prostate: An Updated Review

  2021cites this paper
• The effect of medical and urologic disorders on the survival of patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamide

  2021cites this paper
• Dairy Products: Is There an Impact on Promotion of Prostate Cancer? A Review of the Literature

  2019influential citation
• Risk Analysis of Prostate Cancer Treatments in Promoting Metabolic Syndrome Development and the Influence of Increased Metabolic Syndrome on Prostate Cancer Therapeutic Outcome

  2018cites this paper
• Impact of resistance training on body composition and metabolic syndrome variables during androgen deprivation therapy for prostate cancer: a pilot randomized controlled trial

  2018cites this paper
• Association among metabolic syndrome, inflammation, and survival in prostate cancer.

  2018cites this paper
• A pilot randomised controlled trial of a periodised resistance training and protein supplementation intervention in prostate cancer survivors on androgen deprivation therapy

  2017cites this paper
• Impact of Candidate Genetic Polymorphisms in Prostate Cancer: An Overview

  2016cites this paper
• A review of clinical effects associated with metabolic syndrome and exercise in prostate cancer patients

  2016cites this paper
• Metabolic syndrome in prostate cancer: impact on risk and outcomes.

  2016cites this paper
• Aalborg Universitet Patient Reported Outcomes in a New Home-Based Rehabilitation Programme for Prostate Cancer Patients

  2016cites this paper
• Metformin association with lower prostate cancer recurrence in type 2 diabetes: a systematic review and meta-analysis.

  2015cites this paper
• SIMBOSPROST: Prevalence of metabolic syndrome and osteoporosis in prostate cancer patients treated with radiotherapy and androgen deprivation therapy: A multicentre, cross-sectional study.

  2015cites this paper
• Patient Reported Outcomes in a New Home-Based Rehabilitation Programme for Prostate Cancer Patients

  2015cites this paper
• Metabolic syndrome in castration‐resistant prostate cancer patients treated with abiraterone

  2015cites this paper
• Androgen Receptor Roles in Insulin Resistance and Obesity in Males: The Linkage of Androgen-Deprivation Therapy to Metabolic Syndrome

  2014cites this paper
• Functional and metabolic complications of androgen deprivation therapy

  2014cites this paper
• Molecular imaging of prostate cancer: PET radiotracers.

  2012cites this paper